1. Spinal Muscular Atrophy Market

2. Report Description and Highlights Analyst View: According to Renub Research forecast the global Spinal Muscular Atrophy Market to grow at a CAGR of 14% in the coming years. This high growth rate is primarily due to good reimbursement options in western countries, declining drug prices and projected launch of new drugs. Spinal muscular atrophy (SMA) is one of the most common genomic disorders which are caused due to the loss of specialized nerve cells known as motor neurons in the brainstem and spinal cord. The impairment of motor neurons leads to the weakness and atrophy of muscles used for the regular activities like crawling, sitting, walking and the head movement. In worst cases, the muscles used for breathing and swallowing also get affected. On the basis of severity of muscle weakness, the age of disease commencement, there are four types of spinal muscular atrophy namely type 1, type 2, type 3 and type 4. Type 1, 2 and 3 of spinal muscle atrophy appears in childhood while type 4 appears in adulthood.  One of the major growth drivers witnessing the growth of spinal muscular atrophy market is growing awareness of diagnosis and treatment of spinal muscular atrophy during the forecast period. The awareness about the spinal muscular atrophy diagnosis and treatment is growing among the patients.

3. Spinal Muscular Atrophy Market Additionally, increasing government and non-government support for the treatment and diagnosis of spinal muscular atrophy further boost the growth Global Spinal Muscular Atrophy Market over the coming years. The government of several countries across the world has developed regulations to help medical professionals and caregivers decide when to administer the cure to the infants with spinal muscular atrophy. For instance: In 2018, the Canadian organization of rare disorders signed a petition for funding SPINRAZA for the treatment of Canadian patients with spinal muscular atrophy. Spinal muscular atrophy generally shows its symptoms in early childhood and is a prime cause of mortality in infants. According to Spinal Muscular Atrophy (SMA) Foundation 2015 statistics, spinal muscular atrophy has been affected nearly 10,000 to 25,000 children and adults in the United States. Read more here: https://www.renub.com/spinal-muscular-atrophy-market-p.php

4. Global – Current & Forecast for Spinal Muscular Atrophy Patient Population Share Global – Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 – 2026 Source: Renub Research Analysis Note: These are dummy figures; actual data given in the report

5. Spinal Muscular Atrophy Market Summary • Market Summary • Country-wise, the report provides the Spinal muscular atrophy market and market share of United States, United Kingdom, France, Germany, Spain, Italy and Japan.  • Number of Patients-wise the report provides the total & treated patients population and population share of United States, United Kingdom, France, Germany, Spain, Italy and Japan.  • Drug-wise, the report provides present and estimated global sales of Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070. • Company-wise the report provides present and estimated global of Biogen Inc., Roche AG, Novartis AG andCytokinetics Inc. • Drugs Clinical Phase Study, The report provides 113 Drugs clinical study pipeline status Which is at present, globally in the various stage such as (Phase I, II and III) unknown status, recruiting, active, not recruiting, terminated or completed stage. • Want more Information about this market? Request a free sample copy: • https://www.renub.com/contactus.php

6. Forecast for Spinal Muscular Atrophy Market by Drugs Sales Forecast for Spinal Muscular Atrophy Market by Drugs Sales 2017 – 2026 Source: Renub Research Analysis Note: These are dummy figures; actual data given in the report

7. Key Topics Covered in Spinal Muscular Atrophy Market    Introduction 1.1    Market Definition 1.2    Currency Conversion 2.    Research Methodology 3.    Executive Summary 4.    Global Spinal Muscular Atrophy Market and Patients Analysis 4.1    Spinal Muscular Atrophy Market 4.2    Spinal Muscular Atrophy Patient Numbers4.3    Spinal Muscular Atrophy Treated Patient Number 5.    Share Analysis – Global Spinal Muscular Atrophy 5.1    Country Market Share 5.2    Patients Population Share5.3    Treated Patients Share

8. Key Topics Covered in Spinal Muscular Atrophy Market 6.    United States 6.1    Spinal Muscular Atrophy Market 6.2    Spinal Muscular Atrophy Patient Numbers6.3    Spinal Muscular Atrophy Treated Patients 7.    United Kingdom 7.1    Spinal Muscular Atrophy Market 7.2    Spinal Muscular Atrophy Patient Numbers7.3    Spinal Muscular Atrophy Treated Patient Numbers 8.    Germany 8.1    Spinal Muscular Atrophy Market 8.2    Spinal Muscular Atrophy Patient Numbers8.3    Spinal Muscular Atrophy Treated Patients 9.    Italy – Spinal Muscular Atrophy 9.1    Spinal Muscular Atrophy Market 9.2    Spinal Muscular Atrophy Patient Numbers9.3    Spinal Muscular Atrophy Treated Patient Numbers

9. Key Topics Covered in Spinal Muscular Atrophy Market 10.    France – Spinal Muscular Atrophy 10.1    Spinal Muscular Atrophy Market 10.2    Spinal Muscular Atrophy Patient Numbers10.3    Spinal Muscular Atrophy Treated Patient Numbers 11.    Spain 11.1    Spinal Muscular Atrophy Market 11.2    Spinal Muscular Atrophy Patient Numbers11.3    Spinal Muscular Atrophy Treated Patient Numbers 12.    Japan 12.1    Spinal Muscular Atrophy Market 12.2    Spinal Muscular Atrophy Patients12.3    Spinal Muscular Atrophy Treated Patient Numbers 13.    Drugs Sales – Spinal Muscular Atrophy 13.1    Spinraza 13.2    AVXS-10113.3    CK2127107 13.4    RG791613.5    Olesoxime 13.6    LMI070

10. Key Topics Covered in Spinal Muscular Atrophy Market 14.    Spinal Muscular Atrophy Study Status Analysis 14.1    Spinal Muscular Atrophy Clinical Study 14.2    Spinal Muscular Atrophy Drugs Development Pipeline 15.    Growth Drivers 15.1    Increasing Funding for Research & Development15.2    Biogen Access Programs 16.    Challenges. 16.1    High Treatment Cost 16.2    Common Side Effects 17.    Biogen Inc. 17.1    Business Overview 17.2    Initiatives/Strategies17.3    Financial Insight

11. Key Topics Covered in Spinal Muscular Atrophy Market 18.    Novartis AG 18.1    Business Overview 18.2    Initiatives/Strategies18.3    Financial Insight 19.    Roche Holding AG 19.1    Business Overview 19.2    Initiatives/Strategies19.3    Financial Insight 20.    Cytokinetics, Inc. 20.1    Business Overview 20.2    Initiatives/Strategies20.3    Financial Insight If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com

12. Key Topics Covered in Spinal Muscular Atrophy Market • Browse Related Report : • Epilepsy Drugs Market • Allergic Conjunctivitis Market • Contact Us • Tel: +1-678-302-0700 (US), +91-120-421-9822 (INDIA) • Email: info@renub.com